Ipsen’s Iqirvo(R) receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitisimary biliary cholangitis
The U.S. FDA granted accelerated approval for Iqirvo as a first-in-class PPAR treatment for primary biliary cholangitis. Iqirvo is the first new medicine approved in nearly a decade for this rare liver disease. Clinical Trial Data: The approval was based on positive Phase III ELATIVE trial data. ...
